RWC E-Live CME Series 2022
In this webinar series, experts will focus on major advances in the treatment of retinal diseases, including the optimal use of existing therapies based on clinical evidence. Innovative approaches looking at combination therapies, molecules with novel mechanisms of action, sustained delivery systems, and the use of gene and cell-based therapies will be discussed. Advances in the understanding, diagnosis, and treatment of common and rare retinal diseases will be presented within the context of the therapies being investigated to treat them.
The 2022 CME activity is supported from independent medical education grants from ALCON, APELLIS, REGENXBIO and REGENERON.
Modern Concepts in Retinal Detachment Repair
Recent Sessions
CME E-Live 4: Retinal Detachment
CME E-Live 3 ~ Diabetic and Retina Vein Occlusion Management ~ Diagnostics, Innovative Therapies and Delivery Systems
CME Series Learning Objectives
- Describe how imaging and artificial intelligence systems can guide patient management decisions
- Evaluate innovative gene and cell therapies to prepare for their entry to treat retinal diseases
- Combine and sequence therapies optimally based on response to anti-VEGF and other measures
- Diagnose patients with non-neovascular AMD and differentiate GA from other forms of AMD
- Evaluate innovative therapies and delivery systems based on their ability to improve durability and maintain visual outcomes
- Tailor diabetic eye disease management based on patient-specific factors
- Optimize anti-VEGF therapy in the management of RVO
- Identify preoperative considerations and surgical techniques for repair of retinal detachment
Target Audience
Retina specialists, comprehensive ophthalmologists, retina fellows and residents, and healthcare providers who are interested in applying the most recent advancements in the retinal medicine field, including emerging techniques for imaging and treatments for retinal and vitreoretinal diseases.
Accreditation Information
This activity is jointly provided by Clinical and Patient Educators Association and iVista Medical Education, Inc.
Physician Accreditation Statement
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Clinical and Patient Educators Association (CPEA) and iVista. CPEA is accredited by the ACCME to provide continuing medical education for physicians.
Physician Credit Statement
CPEA designates this live activity for a maximum of 1.5 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
CPEA Contact Information
For information about the accreditation of this program, please contact CPEA at 303-953-4580 or inquire@cpea-assn.org.
Instructions for Obtaining Credit
To receive credit, participants must complete the evaluation. Upon completion, participants will be able to download or email their certificate.
Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. Clinical and Patient Educators Association (CPEA) and iVista do not recommend the use of any agent outside of the labeled indications.
The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Disclaimer
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed in this activity should not be used by clinicians without evaluation of patient conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
This 2022 CME activity is supported from independent medical education grants from Alcon, Apellis, Regenxbio and Regeneron.
